Syenex

Website

Syenex, Inc.

18 Investors
Biotechnology
Evanston, IL

Syenex, Inc. is at the forefront of biotechnology, specializing in advanced delivery technologies for genetic medicine. The company is dedicated to enhancing the field of cell and gene therapy by providing innovative solutions for both in vivo and ex vivo genetic modifications, thereby amplifying the therapeutic potential and clinical impact of these therapies.

Products & Team

Enveloped Delivery Vector Technology

Delivery SystemsSeed

This platform offers a robust solution for genetic medicine applications, focusing on efficient and targeted delivery systems for both ex vivo and in vivo environments. It is designed to overcome the typical barriers in gene therapy such as specificity and efficiency of delivery.

Value Proposition

By facilitating precise and efficient delivery of genetic modifications, it addresses the complex challenge of ensuring that therapeutic genes reach the correct location and exert the intended effects, thereby accelerating the development of effective genetic therapies.

Pain Points

The need for precise and effective delivery of genetic treatments to both ex vivo and in vivo targets

Ex vivo cell engineering solutionsIn vivo delivery systemsTargeted delivery technologies
Industry
Biotechnology
Primary business sector
Founded
2025
Year established
Location
Evanston, IL
Primary headquarters

Funding History

Total Raised:
$8.7M
E

Equity, Option to Acquire Offering

Closed
January 2025
$8.7M
Raised
Progress
100%
Raised
$8.7M
Target
$8.7M
#000193530325000001